Glutamine-fructose-6-phosphate transaminase 1 (GFAT) is the rate-limiting enzyme of the hexosamine pathway that has been implicated in the pathogenesis of diabetic nephropathy. As such, we hypothesized that GFPT1, which encodes for GFAT, may confer genetic susceptibility to this complication among Caucasians. Screening of all known functional regions of GFPT1 revealed six single nucleotide polymorphisms (SNPs) that were located in the promoter, introns, and 3 untranslated region. The ϳ60 kb GFPT1 locus was encompassed in a single conserved haplotype block, and two tagging SNPs were sufficient to capture >90% of the haplotype diversity. Analysis of these SNPs in a case-control study made up of type 1 diabetic subjects (324 case subjects with diabetic nephropathy and 289 control subjects with normoalbuminuria despite >15 years of diabetes) revealed no significant association even after stratification by sex, diabetes duration, glucose control, and blood pressure. Similar results were obtained among type 2 diabetic subjects (202 case and 114 control subjects). Genetic variation in GFPT1 is thus unlikely to have a major impact on susceptibility to diabetic nephropathy. Diabetes 53: [865][866][867][868][869] 2004 
T he hexosamine biosynthetic pathway is an alternative pathway of glucose metabolism that has recently been implicated in the pathogenesis of diabetic nephropathy (1) . Glutamine-fructose-6-phosphate transaminase 1 (GFAT) is the rate-limiting enzyme of this pathway and converts fructose 6-phospate to glucosamine 6-phosphate. Glucosamine 6-phosphate is subsequently converted to uridine diphosphate N-acetylglucosamine, which is used for the O-glycosylation of intracellular proteins, including transcription factors. Concerning diabetic nephropathy, the hexosamine pathway mediates hyperglycemia-induced transforming growth factor-␤1 production by glomerular mesangial cells, an effect that could be prevented by GFAT inhibition (2) . Overexpression of GFAT in rat mesangial cells increases the expression of transforming growth factor-␤1 and its receptors, even under normoglycemic conditions (3) . A similar phenomenon has been reported for NIH-3T3 fibroblasts overexpressing GFAT (4) . Gene expression of plasminogen activator inhibitor-1 is also dependent on the hexosamine pathway as mediated by protein kinase C isoforms and activation of the transcription factor Sp1 by O-glycosylation (3, 5, 6) .
With mounting evidence implicating GFAT in diabetic nephropathy, we hypothesized that GFPT1 (OMIM: 138292, human chromosome 2p13) may be an important susceptibility gene for diabetic nephropathy because it encodes for this enzyme. In this first report to examine the issue, we screened the GFPT1 locus for common DNA polymorphisms by sequencing all known functional regions, including the promoter, all exons, and exon/intron junctions. In total, 17% of the ϳ60 kb locus was screened. Six polymorphisms were detected, all of which were single nucleotide polymorphisms (SNPs) ( Table 1) . One SNP was located ϳ1.1 kb upstream of the start adenine thymine guanine codon (denoted g.-1093AϾG), another in the 3Ј untranslated region (denoted c.2846TϾG), and the remainder in intronic regions (denoted IVS1 ϩ 36CϾT, IVS5 ϩ 25TϾC, IVS5 ϩ 102GϾT, and IVS11 ϩ 7GϾA). All SNPs were common with minor allele frequency ranging from 0.39 to 0.47. Five of the six SNPs were found in dbSNP and one was absent ( Table 1) .
As recent reports have suggested that chromosomal regions contain SNPs that could be partitioned into "haplotype blocks" within which there is substantial linkage disequilibrium (7, 8) , we calculated the linkage disequilibrium between the six SNPs using Lewontin's DЈ, a commonly used measure of linkage disequilibrium (9) . All SNPs were in strong linkage disequilibrium with each other (range of DЈ ϭ 0.88 to 1.00) (data not shown). The frequencies of six SNP haplotypes were estimated from genotype data from 200 randomly selected Caucasian type 1 diabetic individuals (100 case and 100 control subjects). Three haplotypes (denoted A, B, C) predominated, each with an estimated frequency Ͼ0.10. Together, these accounted for Ͼ90% of the haplotype diversity at this locus ( Fig. 1) . A conserved haplotype block thus spans the GFPT1 locus and two tagging SNPs (tagSNPs) (IVS5 ϩ 25TϾC and IVS5 ϩ 102GϾT) were sufficient to define haplotypes A, B, and C (Fig. 1 ).
These tagSNPs were tested for association with diabetic nephropathy using a population-based case-control study design. Among both type 1 and 2 diabetic patients, case subjects were defined as having advanced diabetic nephropathy indicated by persistent proteinuria, chronic renal failure, or end-stage renal disease. Control subjects with type 1 diabetes had normoalbuminuria despite a diabetes duration Ն15 years. Control subjects with type 2 diabetes had normoalbuminuria despite a known diabetes duration Ն6 years, allowing for the fact that the diagnosis of type 2 diabetes is generally established many years after the onset of hyperglycemia. Clinical characteristics of the study groups are shown in Table 2 .
No significant difference in allele or genotype distributions was observed for either IVS5 ϩ 25TϾC or IVS5 ϩ 102GϾT between case and control subjects with type 1 diabetes; estimated haplotype frequencies were also similar between these two groups of patients (Table 3) . Our current findings, therefore, do not support GFPT1 as being an important susceptibility gene for diabetic nephropathy among Caucasians with type 1 or 2 diabetes. This was the case for genotypes at individual SNPs as well as haplotypes formed from the two tagSNPs. This combination of tagSNPs is capable of capturing Ͼ90% of the haplotype diversity at this gene locus in our Caucasian sample, although its performance in other human populations (e.g., Chinese and African populations) should be assessed empirically. Besides reducing the genotyping workload by utilizing tagSNPs, employment of both genoand haplotype analyses also permitted us to evaluate the contribution of common SNPs and currently unidentified, rarer polymorphisms to diabetic nephropathy. Although examination of individual SNPs tested whether their genotypes were common susceptibility determinants of diabetic nephropathy, haplotype analysis addressed the possibility that a putative rarer polymorphism, residing on a haplotype, may also contribute to this genetic risk. Although our study largely excludes a major susceptibility role for GFPT1 for diabetic nephropathy among Caucasians, a minor effect cannot be easily ruled out, and the question as to whether this gene confers susceptibility in other human populations remains open. Genome scans recently conducted at the Joslin Diabetes Center in Caucasian families with type 1 and 2 diabetes have provided suggestive evidence for linkage between diabetic nephropathy and a large region on chromosome 2p that includes GFPT1 (A.S.K., unpublished data). Our current findings, however, do not support this gene locus as being a contributor to these linkage results. Since additional genes are likely related to the hexosamine pathway and its regulation, these may form the focus of future investigations (10). *Haplotypes A, B, and C correspond to haplotypes T-T, C-G, and T-G, respectively, as indicated in Fig. 1 .
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Since 1991, individuals with type 1 diabetes have been recruited for studies of the genetics of nephropathy from among patients attending the Joslin Clinic. Diabetes has been classified as type 1 if it was diagnosed at Ͻ30 years of age and continuous treatment with insulin began within 1 year of diagnosis. As of 2001, 352 case subjects with diabetic nephropathy and 307 control subjects with normoalbuminuria had been enrolled in the study. Details of the procedures for recruiting these patients were described previously (11) . Since 1998, individuals with type 2 diabetes have also been recruited for studies of the genetics of nephropathy from among patients attending the Joslin Clinic. Diabetes has been classified as type 2 if it was diagnosed between ages 30 and 64 years and was treated for at least 2 years with diet or oral hypoglycemic agents. Only patients Ͻ75 years of age at enrollment are included in the study. As of 2002, 303 case subjects with diabetic nephropathy and 168 control subjects with normoalbuminuria had been enrolled into the study. Diagnosis of diabetic nephropathy. The Joslin Clinic provides care for ϳ4,000 patients with type 1 diabetes and 12,000 patients with type 2 diabetes. The majority of these patients are Massachusetts residents referred to the clinic within 5 years of the diagnosis of diabetes. A large proportion of them remain under the care of the clinic for life. Certain demographic and clinical information and most laboratory results are computerized and available for research purposes. The computer databases were used to identify patients eligible for our genetic studies. Diabetic nephropathy was determined on the basis of the medical records of the Joslin Clinic (supplemented with records of other physicians if necessary) and results of routine urinary analyses, including measurements of the albumin-to-creatinine ratio (11) .
Patients were classified as control subjects if they had type 1 diabetes with a duration Ն15 years or type 2 diabetes with a duration Ն6 years and their albumin-to-creatinine ratio was Ͻ17 mg/g for men or Ͻ25 mg/g for women in at least two of the last three urine specimens spanning at least a 2-year interval. Patients with microalbuminuria or intermittent proteinuria were not included in this study. Patients were considered case subjects if they had persistent proteinuria or if they had end-stage renal disease due to diabetic nephropathy. Persistent proteinuria was defined as two of three successive urinalyses positive by either reagent strip (Ն2ϩ on Multistix; Bayer, Elkhart, IN) or an albumin-to-creatinine ratio Ն250 mg/g for men or Ն355 mg/g for women. Patients with persistent proteinuria and serum creatinine Ն2.0 mg/dl were considered case subjects with chronic renal failure. Examination of study participants. All patients selected for the genetic studies were examined at the clinic or at their homes. After consenting to participate in the study, each subject had a standardized physical examination and provided a diabetes history regarding diagnosis, treatment, and complications. Each individual provided a blood sample for biochemical measurements and DNA extraction. Patient medical records were thoroughly reviewed to minimize the possibility of the presence of nondiabetic kidney disease, and patients were also directly questioned whether they were ever diagnosed for nondiabetic kidney disease by MDs. The Committee on Human Subjects of the Joslin Diabetes Center approved the protocols and informed consent procedures for our studies. GFPT1 DNA polymorphisms screening. GFPT1 consists of 20 exons, including a recently described alternative exon (12, 13) . To identify DNA polymorphisms in GFPT1, all exons (with exon/intron boundaries) and 1.5 kb of the promoter region were amplified from the genomic DNA of eight individuals (four case and four control subjects) using PCR (online appendix 1 [available at http://diabetes.diabetesjournals.org]). PCR (25 l reaction volume) was typically performed on 20 ng of genomic DNA using 0.6 units of Taq polymerase (PGC Scientific) in the presence of 1.5 mmol/l MgCl 2 for 40 cycles. Cycling parameters were denaturation at 95°C for 45 s, annealing at product-specific temperatures (Table 1) for 45 s, and extension at 72°C for 60 s with final extension at 72°C for 10 min. Primer sequences were designed based on human GFPT1 genomic DNA sequence (GenBank accession number NT_022184). All PCR products were sequenced using an ABI 377 automated DNA sequencer in conjunction with dye terminator chemistry in accordance with the manufacturer's protocol (Perkin Elmer). DNA sequence chromatograms were manually inspected to ensure proper base calling by the sequencing analysis software. As the PCR products were 500 bp in length on average, sequencing them from both forward and reverse directions resulted in considerable sequence overlap. This allowed us to double check the detection of DNA polymorphisms. Polymorphisms were annotated according to the nomenclature advocated by Antonarakis and the Nomenclature Working Group (14) . Genotyping. When this study was performed, genomic DNA was available for genotyping from 289 (94%) and 324 (92%) type 1 diabetic control and case subjects, respectively, as well as 114 (68%) and 202 (67%) type 2 diabetic control and case subjects, respectively. Almost one-third of the patients with type 2 diabetes did not have DNA extracted as of the time of this study. Those with DNA available were not different from those without DNA with regard to sex, age at examination, duration of diabetes, or clinical characteristics such as distribution of HbA 1c or blood pressure.
Genotyping of GFPT1 polymorphisms was performed by DNA hybridization using allele-specific oligonucleotides probes, as previously described (15) . DNA sequences of the allele-specific oligonucleotide probes and PCR primers are detailed in Table 1 . The two tagSNPs, IVS5 ϩ 25TϾC and IVS5 ϩ 102GϾT, were also genotyped as restriction fragment length polymorphisms. IVS5 ϩ 25TϾC was genotyped using PshAI (New England Biolabs, Beverly, MA) so that when the C allele was present, the restriction site was absent and the 581-bp PCR product migrated intact as a single band. When the T allele was present, two bands of sizes 302 and 279 bp were seen after digestion. For IVS5 ϩ 102GϾT, genotyping was performed using AseI (New England Biolabs). When the G allele was present, the restriction site was absent, but when the T allele was present, digestion occurred and two fragments of 383 and 198 bp were seen. Genotypes of 80 individuals obtained using allelespecific oligonucleotides and restriction fragment length polymorphism methods were in strong agreement for both IVS5 ϩ 25TϾC (99% concordant) and IVS5 ϩ 102GϾT (100% concordant), consistent with the absence of any significant genotyping error. Statistical analysis. Data on the study groups were compared using 2 and Student's t tests for categorical and continuous variables, respectively (SAS system for Windows version 6.12; SAS Institute, Cary, NC). Identification of haplotype blocks was performed according to Gabriel et al. (8) with DЈ Ն0.8 as evidence of strong linkage disequilibrium. Haplotype frequencies were estimated using the EM algorithm in SAS. Within each haplotype block, tagSNPs were identified that best captured the diversity of common haplotypes present (i.e., those with frequencies Ն5%). Power analysis. Power analysis was performed with an ␣ (type 1 error) set at 5%. Based on sample sizes of 289 control subjects and 324 case subjects for patients with type 1 diabetes, power to detect a ⌬ of 0.1 in allele frequency of the tagSNPs was Ͼ90%. For sample sizes, 114 control subjects and 202 case subjects for patients with type 2 diabetes, power to detect ⌬s of 0.1 and 0.15 in allele frequency was 70 and 95%, respectively.
